Yahoo Finance

Paris – October 16, 2024 – Olivier Falut has been appointed EUROAPI’s Chief Financial Officer, effective October 17, 2024, and will be a member of the Executive Committee. He is taking over from Evelyne Nguyen, who will remain within the company until the end of October to ensure a smooth transition.

“I am delighted to welcome Olivier, a seasoned Chief Financial Officer with extensive experience in the industrial sector. He will play a decisive role in implementing our FOCUS-27 transformation project,” said Ludwig de Mot, EUROAPI Chief Executive Officer. “The entire company and the Board of Directors join me in expressing our sincere gratitude to Evelyne for succeeding in her mission to ensure the financing of our strategic plan.”

Olivier Falut joins EUROAPI with close to 30 years of experience in management and finance in the industrial sector. Throughout his career, he held various financial positions in listed and non-listed companies, such as Fareva, Limagrain (including Vilmorin & Cie), Lactalis and Bel.

“I am excited to be joining EUROAPI and to be part of the implementation of the FOCUS-27 transformation plan. This new economic dynamic will enable us to carry out major projects and to ensure the sustainable growth of the organization for the years to come,” Olivier Falut said.

Olivier Falut professional background
Olivier Falut started his career in the financial audit sector, mainly at Ernst & Young in France and then in the United States. In 2001, he joined Bosch France as head of accounting and pursued his career as accounting director at Bel in 2003. In 2008, he joined Oberthur Technologies as CFO for the main business unit before moving to Lactalis (2012-2017) as head of group financial control. Since 2017, he has held CFO positions in various companies including Sodiaal, Segula Technologies, Limagrain and Fareva.

Olivier Falut is a graduate from ESSEC business school and holds master’s degrees in business law. He also graduated from the French bar exam.

About EUROAPI
EUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers’ and patients’ needs around the world. We are a leading player in active pharmaceutical ingredients with approximately 200 products in our portfolio, offering a large span of technologies while developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities.

Taking action for health by enabling access to essential therapies inspires our 3,650 people every day. With strong research and development capabilities and six manufacturing sites, all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries. EUROAPI is listed on Euronext Paris; ISIN: FR0014008VX5; ticker: EAPI). Find out more at www.euroapi.com and follow us on LinkedIn.